脑梗死早期应用依达拉奉治疗的临床观察  

Clinical Study of Edaravone on Early Period of Cerebral Infarction

作　　者：李慧明[1] 李剑[1] 李明[1] 洪翔[1] 

机构地区：[1]深圳市龙岗中心医院神经内科,广东深圳518116

出　　处：《药物流行病学杂志》2005年第5期265-266,共2页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:评价依达拉奉对脑梗死患者早期应用的疗效及安全性。方法:选择发病72 h以内的脑梗死患者,随机分为治疗组(35例)及对照组(35例)。治疗组给予依达拉奉注射液30 mg ivd,bid,共14 d,同时给予对照组的基础治疗;对照组给予疏血通6 ml ivd,qd,共14 d,同时给予口服肠溶阿司匹林0．1 g,qd。治疗前、治疗后第7 天、第14天、第21天对患者进行欧洲卒中评分(ESS)、日常生活活动能力评定(ADL)和常规检查。结果:第14天治疗组、对照组ESS值分别为(73．8±18．6)、(63．2±13．8),两组比较差异显著(P<0．01),ADL值分别为(75．1± 21．6)、(61．3±17．5),两组比较差异显著(P<0．01)。结论:依达拉奉能有效改善发病早期的脑梗死患者近期的神经功能缺损和日常生活能力,未发现有严重的不良反应。Objective： To explare the efficacy and safety of edaravone, on the early period of cerebral infarction. Method： Cerebral infarction patients come on within 72 h were elected, 70 patients were randomly divided into therapeatic group （ n = 35 ） and controlled group （ n = 35 ）. The theyatupic group was used edaravone 30 mg, ivd, bid, for 14 days, meantime, they was taken basic treatment as controlled group. The controlled group was given shuxuetong 6 ml, ivd, qd and aspirin 0.1 g po. qd. for 14 day. Before treatment and 7th, 14th, 21st day after treatment, European Stoke Scale （ESS）, activity of daily living（ADL） and routine examination were determined. Result： At the 14th day, the ESS value of the therapeutic group and the controlled group were （ 73.8±18.6） and （ 63.2 ±3.8 ） respectively （ P 〈 0.01 ）. The ADL value of two groups were （75.1±21.6） and （61.3±17.5 ）respectively（p 〈 0.01 ）. Conclusion： Edaravone can improve the deficiency of the neurologic functions and ADL on early period of cerebral infarction, and it has no serious adverse reaction.

关 键 词：依达拉奉 脑梗死 自由基清除剂 

分 类 号：R743.3[医药卫生—神经病学与精神病学]